Yes this is more than just Janssen. The thing the market is really missing is it avoids the distribution problem as the pharma companies will take care of this.
It also potentially put PIQ in play between the various pharma companies as a means of making their drug standout from the crowd. If one of the pharma companies buys out PIQ they can use the PIQ's tests for when a pharma rep goes and visits a doctor. The rep can say with our drug can get real objective data on if the drug is actually helping the patient.
I should probably shut up as I haven't bought yet
Ann: Appendix 4C - March 2019 Quarterly Report, page-15
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.015(4.92%) |
Mkt cap ! $47.42M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 31.0¢ | 28.5¢ | $191.2K | 643.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 53694 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 51000 | 2 |
View Market Depth
| Last trade - 15.36pm 26/06/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |